New York, NY, and Tel Aviv, ISRAEL, Aug. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTC-BB:TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned joint venture 3CL Pharma Ltd. reported the preprint in ResearchGate of a case study entitled “Tollovid as a Rescue Agent for Paxlovid Rebound in Acute COVID-19” overseen by Dr. Lee Morgentaler in concert with Andrew A. Blumenthal, RN ADS of a patient with Post-Acute Sequelae of COVID (PASC, or “Long COVID”) who experienced multiple reinfections with SARS-CoV-2 virus over 27 months and experienced full COVID symptom resolution with a 5-day course of Paxlovid® treatment following positive PCR after which the patient immediately experienced COVID rebound that was resolved following consumption of supplementation with 3CL protease inhibitor immune support dietary supplement Tollovid™. The pre-publication can be viewed at: https://www.researchgate.net/publication/362387662_Tollovid_as_Rescue_Agent_for_Paxlovid_Rebound_in_Acute_Covid-19 .
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20logo%20on%20mobile%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
